⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31328741 | 1.00 | — | — | |
| SCHEMBL29080087 | 1.00 | — | — | |
| SCHEMBL26197960 | 1.00 | — | — | |
| SCHEMBL31328578 | 1.00 | — | — | |
| SCHEMBL30391527 | 1.00 | — | — | |
| SCHEMBL23043281 | 0.82 | HTR1A (0.32) | — | |
| SCHEMBL29680450 | 0.82 | HTR1A (0.32) | — | |
| SCHEMBL31732899 | 0.81 | — | — | |
| SCHEMBL25180363 | 0.75 | MAPT (0.31) | — | |
| SCHEMBL25379434 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2025040767-A1 | 2-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1,3,5-TRIAZINE DERIVATIVES AS KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2025-02-27 | — | — | WO | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-116829151-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4182313-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2022015375-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |